Project Grant R01CA286780
Award Date
7/1/24
Completion Date
6/30/29
Dollars Obligated
$679K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Cold Spring Harbor, NY 11724, USA
Similar Awards
This $249,000 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports research to decode the evolution and progression of glioma, an incurable brain cancer. The research aims to develop a multi-dimensional model of glioma progression by leveraging novel single-cell technologies to concurrently profile the transcriptome, epigenome, and genome of glioma cells. This will elucidate how somatic mutations and epigenetic changes...
This federal Project Grant award of $954,000 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the University of Pittsburgh aimed at understanding how aging promotes the growth and survival of glioblastoma, an aggressive type of brain cancer. The research will leverage insights from the aging nervous system and the molecular circuitry of cancer stem cells to investigate metabolic alterations within the aging tumor microenvironment. Using spatial...
The National Cancer Institute awarded a $417,858 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Brigham & Women's Hospital Inc. to develop novel cellular therapies for the treatment of glioblastoma (GBM), a highly malignant brain tumor. The project aims to engineer mesenchymal stem cells (MSCs) to release bi-specific T cell engager (BiTE) molecules targeting EGFR/EGFRvIII and IL13Rα2 antigens expressed on GBM cells. The engineered MSCs will be encapsulated in a synthetic...
The National Cancer Institute (NCI) awarded a $655,306 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Regents of the University of California, San Francisco (UCSF) to conduct research on leveraging reactive metabolite generation in brain tumors. The key objectives are: Determining if the combination of the Glyoxalase 1 (GLO1) inhibitor BBG with radiation is an effective therapeutic strategy for treating isocitrate dehydrogenase (IDH)-mutant gliomas, a deadly form of brain cancer....
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $399,214 to Proton Bio, Inc. to conduct research on targeting the proton-sensing receptor GPR68 as a potential therapeutic approach for treating glioblastoma (GBM), the most common and aggressive form of brain cancer. The key objectives are to: 1) Define the in vitro pharmacological properties of three lead Ogremorphin compound candidates, 2) Determine the pharmacokinetics and brain...
This $800,000 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel biologic therapy by Creative Biotherapeutics LLC to eradicate primary and metastatic brain cancers. The research aims to target the extracellular glucose-regulated protein 78 (eGRP78), which is upregulated in drug-resistant brain tumors and enhances cancer stem cell formation, drug resistance, and immune evasion. Preclinical studies in mice have...
The federal Project Grant award, provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), is supporting research at Case Western Reserve University (CWRU) to study translation regulation in glioblastoma stem-like cells (GSCs) and their adaptation to hypoxic tumor environments. The $107,948 award, effective January 9, 2025 through July 16, 2028, will employ ribosome profiling and RNA sequencing techniques to quantify the influence of hypoxia on translational...
This $458,021 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Mayo Clinic will support research aimed at maximizing the efficacy of MDM2 inhibitor therapy for MDM2-amplified glioblastoma, a highly aggressive form of brain cancer. The key objectives are to: Evaluate the mechanism behind the exquisite sensitivity of MDM2-amplified glioblastoma to the MDM2 inhibitor Brigimadlin. Define the effects of Brigimadlin on the cellular response to...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of a combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The $609,749 award to the University of North Carolina at Chapel Hill aims to: Develop an injectable, biodegradable hydrogel scaffold that can deliver high concentrations of induced neural stem cells (iNSCs) for...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $451,996.00 to the University of Texas at Arlington (UTA) to develop and utilize a high-throughput platform for identifying and validating drugs that can target treatment-resistant glioblastoma (GBM) cells. The key objectives are to: (I) employ an ex vivo integrated high-throughput platform to quantitatively analyze malignant, therapy-resistant brain cancer cells and assess their...